This is the authors' abstract. We don't add key points for this paper.
Antibody-based drugs have been a significant breakthrough in the field of cancer treatment in recent years with the development of biotechnology in pharmaceuticals. These drugs utilize artificially synthesized antibodies to target specific antigens on cancer cells for targeted therapy. Bispecific antibodies (BsAbs) and antibody–drug conjugates (ADCs) are emerging classes of antibody-based drugs. Currently, there are five approved BsAbs and fifteen approved ADCs globally for the treatment of various solid tumors and hematological malignancies. BsAbs can target two different antigens, allowing for more precise targeting, increased specificity, and reduced toxicity. ADCs consist of antibody, linker, and payload, offering improved efficacy and reduced side effects. This article provides an overview of approved BsAbs and ADCs globally, including their characteristics, therapeutic targets, indications, clinical efficacy, and safety profiles, aiming to provide insights into the global development of these types of drugs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: